Literature DB >> 9570169

Treatment of Helicobacter pylori infection.

J A Salcedo1, F Al-Kawas.   

Abstract

Since acceptance of the association between Helicobacter pylori and peptic ulcer disease, eradication of H. pylori has become the standard of care in the treatment of peptic ulcer disease. Unfortunately, eradication therapy is no easy task, especially when one is faced with a myriad of drug combinations with varying degrees of efficacy and tolerability. The following is a review of the literature regarding the drugs and drug combinations used to eradicate H. pylori and their effectiveness both as single agents and in combination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570169     DOI: 10.1001/archinte.158.8.842

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  Coexistence of eosinophilic gastroenteritis and Helicobacter pylori gastritis: causality versus coincidence.

Authors:  M J Muller; G S Sewell
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

2.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay.

Authors:  D E Roth; D N Taylor; R H Gilman; R Meza; U Katz; C Bautista; L Cabrera; B Velapatiño; C Lebron; M Razúri; J Watanabe; T Monath
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  Protective Effects of Silibinin on Helicobacter pylori-induced Gastritis: NF-κB and STAT3 as Potential Targets.

Authors:  Kyunghwa Cho; Hee Geum Lee; Juan-Yu Piao; Su-Jung Kim; Hye-Kyung Na; Young-Joon Surh
Journal:  J Cancer Prev       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.